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WE ARE NEW YORK’S LAW SCHOOL
New York Law School—Pegalis & Erickson Health Law Colloquium

EXAMINING THE INTERSECTION OF
BIOETHICS AND THE LAW IN 2018
Hosted by Trustee and Professor Steven E. Pegalis ’65

DATE
April 30, 2018
TIME
6:00 p.m.–7:45 p.m.
LOCATION
New York Law School
Auditorium
185 West Broadway
New York, NY 10013
COST
Free
CLE
2 credits in Ethics
and Professionalism.
(NY transitional
and non-transitional)
RSVP
nyls.edu/pegalislecture

This CLE will include a focus on clinical decision-making, palliative and
end-of-life care, dispute resolution, medical and social science research,
and informed consent and decision-making.
MODERATOR
Adam Herbst Esq., M.B.A., Chief Legal Officer, Blythedale Children’s
Hospital and Adjunct Professor, New York Law School
PANELISTS
Joanne T. Haberlin ’90, R.N., B.S.N., Senior Counsel, NYC Health + Hospitals
Karen L. Illuzzi Gallinari ’88, Esq., Health Law, Compliance, and
Bioethics Specialist
Nancy Neveloff Dubler, LL.B., Consultant for Ethics, NYC Health +
Hospitals and Adjunct Professor, Division of Medical Ethics, NYU Langone
Medical Center
Mary Beth Quaranta Morrissey, Ph.D., M.P.H., J.D., Fellow, Fordham
University’s Global Healthcare Innovation Management Center and Senior
Policy Advisor in Health and Ethics, Finger Lakes Geriatric Education Center,
University of Rochester Medical Center
CO-SPONSORS
Impact Center for Public Interest Law • Diane Abbey Law Institute for
Children and Families • Patient Safety Project

New York Law School is certified by the New York State Continuing Legal Education Board as
an Accredited Provider of continuing legal education in the State of New York. The School has
been serving the legal education needs of the greater New York area for more than 125 years,
including the continuing educational needs of its graduates and other area attorneys.

PEGALIS & ERICKSON HEALTH LAW COLLOQUIUM
AT NEW YORK LAW SCHOOL

EXAMINING THE DYNAMIC INTERSECTION OF
BIOETHICS AND THE LAW IN 2018
April 30, 2018
(6:00pm – 7:45pm)
Hosted by Professor Steve Pegalis

Moderated by Professor Adam Herbst

The American legal system has played a dramatic role in shaping the field of bioethics. The
dynamic intersection of law and bioethics is a fruitful area of inquiry for purposes of knowledge
generation, policy making and best practices. Reflecting a diversity of perspectives, this CLE will
examine the crucial connection between law and matters bioethical in 2018. The program will
include a focus on clinical decision making, palliative and end-of-life care, dispute resolution,
medical and social science research, and informed consent and decision making.
CLE Details: NYLS is accredited by the State of New York to offer this program with 2 Credits of
Ethics and Professionalism Continuing Legal Education. Transitional and Non-Transitional use.
AGENDA
6:00pm Welcome – Anthony W. Crowell, Dean and President of New York Law School
6:05pm Introductory Remarks – Steve Pegalis ’65, Founding Partner, Pegalis & Erickson, LLC,
NYLS Adjunct Professor, NYLS Trustee
6:10 – 7:55pm Panel Discussion Moderated by Adam Herbst, Chief Legal Officer, Blythedale
Children’s Hospital

Host and Panelist Bios:
Steven E. Pegalis is the founding partner of Pegalis & Erickson, LLC and one of the nation’s
foremost medical malpractice trial lawyers. In his nearly 50 years practicing law as an advocate
for seriously injured victims of negligence he has obtained some of the highest jury verdicts. He
is most proud of providing peace of mind, a sense of justice, and financial security to more than
2000 clients to date.
Stacks of photos and thank-you notes from clients’ families are among his most prized
processions. He believes his team’s personal investments in each case are without peer, and
has resulted in consistent success for patients year after year. He and his firm have worked
tirelessly with some two thousand injured individuals and their families. For example: in 1998,
he obtained a $116 million jury verdict for a brain injured child, and in 2004 he obtained a
$111.7 million verdict for a brain injured child.
Pegalis is the only lawyer to be named both the 2017 “Lawyer of the Year” on Long Island, for
Plaintiffs’ Personal Injury Litigation, and the 2016 "Lawyer of the Year," for Plaintiffs’ Medical
Malpractice lawyer in New York, by Best Lawyers© and Best Lawyers in America®. The “Lawyer
of the Year” distinction reflects the high level of respect a lawyer has earned among other
leading lawyers in the region and practice areas for their abilities, professionalism, and
integrity. Additionally in 2016, Pegalis was honored with a Lifetime Achievement Award by the
New York State Trial Lawyers Association (NYSTLA). In 2015, Pegalis was named co-director with
Irwin R. Merkatz, MD, of the Patient Safety Project initiative at New York Law School (NYLS),
focused on making significant contributions to medical safety and promoting innovative health
law policies for the public good. Also in 2015, Pegalis was honored with the Nassau County Bar
Association's WE CARE Fund award. Pegalis is the author of American Law of Medical
Malpractice, Volumes 1-3, now in its 3rd edition. He serves on the NYLS Board of Trustees, was
an Adjunct Professor of Law, and was honored with school's Groundbreaker Award for a
lifetime commitment to his clients, and successfully pursuing their rights with passion.
Pegalis is an advocate of the American Board of Trial Advocacy, a Dean of the New York State
Trial Lawyers Institute, and a member of the American Association for Justice, and the National
Board of Trial Advocacy. He is an Associate in Law of the American College of Legal Medicine,
and is AV rated on Martindale-Hubbell for professional excellence. Each year he is voted to
the Best Lawyers® List in New York and the New York Super Lawyers List. Pegalis has lectured
extensively on medical/legal issues, and contributed his experience and viewpoint to numerous
articles and publications. He is admitted to practice in New York, the U.S. Court of Appeals, 2nd
Circuit, and the U.S. District Courts for the Eastern and Southern Districts of New York. He holds
both a Juris Doctor and Bachelor of Law degree from New York Law School, and a Bachelor’s
Degree from Queens College of the City of New York.
EDUCATION
New York Law School, JD
Queens College of the City of New York, Bachelor's Degree

BAR Admissions/Qualifications
New York
Southern District of New York
Eastern District of New York
Joanne T. Haberlin, R.N., B.S.N., J.D. (NYLS ‘90)
Ms. Haberlin is both a registered nurse and an attorney. She is also a graduate of New York Law
School. She currently holds the position of Senior Counsel at NYC Health and Hospitals, the
nation’s largest public health care system. Her area of practice focuses on health care and
medical legal issues in the acute, long term care, and ambulatory settings.
She provides legal guidance on complex issues both on a real time basis in the clinical setting
and in formal training sessions to an array of staff, including physicians, nurses, social workers,
bioethics committees and other providers. These issues relate to consent and surrogate
decision making involving the acceptance, refusal, or objection, to beneficial treatment; the
withholding and withdrawal of treatment; and end of life of issues.
Prior to her current position she held the position of Senior Director of Corporate Risk
Management for NYC Health +Hospitals and Senior Director of Risk Management for NYC
Health + Hospitals /Elmhurst. Prior to joining NYC Health + Hospitals, she was a litigating
attorney at the law firms of Bower and Gardner and Bartlett, McDonough, Bastone and
Monaghan. Her practice was focused on medical malpractice litigation. Prior to attaining her
law license, she practiced as a registered nurse at New York University Medical Center.
Nancy Neveloff Dubler, LL.B.
Ms. Dubler is a consultant for Bioethics at New York City Health and Hospitals and Adjunct
Professor in the Division of Medical Ethics, NYU Langone Medical Center. She is Professor
Emerita at the Albert Einstein College of Medicine and former director of the Division of
Bioethics at Montefiore Medical Center and the Albert Einstein College of Medicine. She
received her B.A. from Barnard College and her LL.B. from the Harvard Law School. She lectures
extensively and is the author of numerous articles and books on termination of care, home care
and long-term care, geriatrics, AIDS, adolescent medicine, prison and jail health care, Clinical
Ethics Consultation, and Bioethics Mediation. Her most recent books are: Bioethics Mediation:
A Guide to Shaping Shared Solutions, co-author, Carol Liebman, Vanderbilt University Press,
2011; The Ethics and Regulation of Research with Human Subjects, Coleman, Menikoff, Goldner
and Dubler, Lexis/nexis, 2005, Supplement 2012; Ethics for Health Care Organizations: Theory,
Case Studies, and Tools, with Jeffrey Blustein and Linda Farber Post (2002). She consults often
with federal agencies, national working groups and bioethics centers.
Mary Beth Quaranta Morrissey, Ph.D., M.P.H., J.D.

Converging Perspectives in Bioethical Inquiry and Public Health Ethics: Addressing the Problem
of Equity in Palliative and End-of-Life Care
Dr. Morrissey is a New York health care attorney and a gerontological health and social work
researcher. She holds the appointments of Fellow at Fordham University’s Global Healthcare
Innovation Management Center, and Senior Policy Advisor in Health and Ethics, Finger Lakes
Geriatric Education Center (FLGEC), University of Rochester Medical Center. She directs
the Aging & Health Workforce Development Institute, a project of the Collaborative for
Palliative Care, FLGEC and the Westchester Public Private Partnership for Aging Services. Dr.
Morrissey is President-elect and Treasurer of the American Psychological Association Society for
Theoretical and Philosophical Psychology, President of the National Committee for the
Prevention of Elder Abuse, Founder and President of the Collaborative for Palliative Care, New
York, Chair of the New York City Bar Association Bioethical Issues Committee, and Chair of the
Westchester County Bar Association Health Law Committee. She is a member of the New York
State Bar Association Health Law Section, Ethical Issues Committee and Public Health
Committee, and is past president of the State Society on Aging of New York and immediate past
president of the Public Health Association of New York City. Morrissey’s research and
scholarship on pain, suffering and end-of-life inform and guide her practice and advocacy. She
has authored numerous publications in law journals and peer-reviewed scientific journals,
integrating law, public health and bioethical perspectives. As Chair of the City Bar Bioethical
Issues Committee, she led the development and was the leading author of the recently issued
City Bar Commentary on Medical Aid in Dying in New York (June 2017).
Karen L. Illuzzi Gallinari, Esq. (NYLS ’88)
Ms. Gallinari has over 20 years’ experience in healthcare law, compliance, medical research and
bioethics. Most recently, as a Senior Compliance Officer for NYC Health + Hospitals, Karen
assisted NYC Health + Hospitals Office of Corporate Compliance with implementation of NYC
Health + Hospitals’ Compliance Program. She also is an officer on the Executive Committee of
the NYS Bar Association’s Health Law Section, a member of the Health Law Section’s
Biotechnology and Medical Research Committee and is a member of the NY City Bar
Associations’ Health Law Committee’s Bioethical Issues Subcommittee.
Her previous leadership roles include co-chairing a national collaboration of medical research
centers through which she facilitated education and dialog on bioethics issues relating to
medical research. As Director of Regulatory Affairs for Research at Montefiore Medical Center
(“MMC”), Karen was charged with advancing MMC’s and the Albert Einstein College of
Medicine’s DNA Biobank. She also served as MMC’s Privacy Officer and Director of
Compliance. In that role, she worked on electronic health data security, privacy law and
compliance policy training and implementation.
Karen was formerly Vice President of Legal Affairs and General Counsel for Staten Island
University Hospital, also served as Vice President for Patient and Family Services for the
American Cancer Society, chaired the In-House Counsel Committee for the Health Law Section
of the New York State Bar Association and served as NYS Chair of the National Patient Advocate

Foundation. Under Karen’s leadership, the NPAF’s New York advocacy team was successful in
securing a New York State Resolution urging an amendment to Medicare to permit insurance
coverage for oral cancer drugs.
Prior to joining SIUH in 1996, she was a litigator with the firm of Anderson Kill Olick & Oshinsky,
P.C. Karen applied the firm’s insurance coverage expertise to patients and medical institutions
seeking to secure insurance coverage for state-of-the-art medical treatments. She also
organized a national network of pro-bono attorneys experienced in handling health insurance
disputes. Karen is a graduate of New York Law School, Class of 1988.
Adam S. Herbst, Esq., MBA
Mr. Herbst is Chief Legal, Planning and Government Relations Officer for Blythedale Children’s
Hospital. He also serves as the Hospital’s Chief Compliance Officer. In this role, Mr. Herbst has
legal and compliance oversight for the Hospital and is responsible for developing corporate
planning strategies and administering government relations, the ethics program, as well as
advocacy and community relations.
Mr. Herbst has devoted a considerable portion of his career specializing at the intersection of
where health care law meets with communications, technology and ethical issues. Mr. Herbst
has worked on issues related to housing, education, public health, economic development and
has trial experience in both federal and state courts, as well as arbitrations throughout the
country. He is a frequent speaker on health care access and informed consent.
Mr. Herbst is an Adjunct Professor at New York Law School, teaching Health Law and Policy, and
is also the Co-Director of the Health Law Clinic.

Intersection of New York State Laws
and Bioethics in the Clinical Setting
Joanne Haberlin, R.N.,B.S.N., Esq.

Intersection
Bioethics and New York State Public Health Laws
The discipline of bioethics potentially interplays in situations in which certain laws are integrated or
triggered in the clinical setting:
•
•
•

Consent (N.Y.S. Public Health Sections 2504; 2803; 2805)
Health Care Agents and Proxies (N.Y.S. Public Health Law Section 2981;2982)
Family Health Care Decisions Act ( N.Y.S. Public Health Law Section 2994)

Common Theme
• Autonomy for health care decisions
• Maintaining control of medical decisions even after the loss of decision making capacity.

Informed Consent
Discussion Between Health Care Provider/ Patient or Legally Authorized Representative
Risks, Benefits and Alternatives
N.Y.S. Public Health Law Sections 2803- c; 2504; 2805-d
N.Y.S. Public Health Law Section 2504
N.Y.S. Public Health Law Section 2504 delineates in detail those individuals authorized to consent to health care and the limitations related to the
consent for treatment
Basic premise
Any person who is eighteen years of age or older, or is the parent of a child, or has married, may give effective consent for medical, dental, health
and hospital services for himself or herself, and the consent of no other person shall be necessary.
Patient's Bill of Rights
N.Y.S. Public Health Law Section 2803(c) states as follows:
Every patient shall have the right to receive adequate and appropriate medical care, to be fully informed of his or her medical condition and proposed treatment,
unless medically contraindicated, and to refuse medications and treatment after being fully informed of and understanding the consequences of such actions.
N. Y. S. Public Health Law Section 2805 -d)
PHL Section 2805 d limits a cause of action for lack of informed consent but also establishes the threshold standard for this cause of action.
It is the failure of the person providing the professional treatment or diagnosis to disclose to the patient such alternatives and the reasonably foreseeable risks and
benefits involved as a reasonable medical, dental or podiatric practitioner under similar circumstances would have disclosed, in a manner permitting the patient to
make a knowledgeable evaluation.
Case Law
To establish a cause of action to recover damages for malpractice, based on lack of informed consent, a plaintiff must prove that the person providing the
professional treatment failed to disclose alternatives, and failed to inform the patient of reasonably foreseeable risks associated with the treatment, and the
alternatives, that a reasonable medical practitioner would have disclosed under the same circumstances; and that a reasonable prudent patient in the same
position would not have undergone the treatment if he or she had been fully informed; and that the lack of informed consent is a proximate cause of the injury
(Zappatta v. Buitriago,969 N.Y.S.2d 79 2d., Dept. 2013).

Legally Authorized Representatives and Bioethics
In the context of Bioethics in the clinical setting, these Legally Authorized
Representatives often emerge:
• Health Care Agents (N.Y.S. Public Health Law Section 2981)
• Surrogates (N.Y.S. Public Health Law Section 2994-d)
Comparison:
• Health Care Agent - appointed by the patient.
• Surrogate - appointed by statute.

Health Care Agents and Proxies
N.Y.S. Public Health Law Sections 2981; 2982
Health Care Proxy - N.Y.S Public Health Law Section 2981
•
A competent adult has the legal authority to appoint a health care agent to make health care decisions on his or her behalf when
he or she is unable to make such decisions due to a lack of capacity.
•
The document must be signed by the adult in the presence of two adult witnesses, who shall also sign the proxy. Another person
may sign and date the health care proxy for the adult, if the adult is unable to do so, at the adult’s direction and in the adult’s
presence and also in the presence of two adult witnesses who shall sign the proxy.
•
The witness shall state that the principle appeared to execute the proxy willingly and free from duress.
•
The person appointed as agent shall not act as witness to the execution of the health care proxy.
Standards for Health Care Agents - N.Y.S. Public Health Law Section 2982
Subject to any express limitations in the proxy, an agent shall have the authority to make any and all health care decisions on the
principles’ behalf that the principle could make under the law.
•
The agent must first consult with a professional before making a decision and must make decisions in accordance with the
principle’s wishes, or, failing that, in the principle’s “best interest” (except for artificial nutrition and hydration if the wishes are not
reasonably known or reasonably ascertainable).
•
The agent takes priority over other potential surrogates, except the agent does not supersede any authority that the principle
may have under law to make or express decisions ,wishes, or instructions regarding health care, including life sustaining
treatment.
•
The authority of the agent commences upon the determination by an attending physician that the principle lacks capacity to
make decisions.

Family Health Care Decisions Act
N.Y.S. Public Health Law Article 29-CC
The Family Health Care Decision Act has established a procedure to facilitate responsible decision making on behalf of
patients who lack capacity, who have not:
Appointed a Healthcare Agent pursuant to and in accordance with Public Health Law Section 2981.
Provided clear and convincing evidence of treatment decisions.
Authorizes a surrogate to make decisions for both beneficial and end of life decisions.
Exclusions
•
Court appointed guardians under Section 1750(b) of the Surrogate Court Procedure Act.
•
Decisions that can be made by a family member or friend under Section 1750(b) of the Surrogate Court Procedure Act.
•
Decisions pursuant to New York State Mental Health regulations and OMRDD surrogate decision making regulations.
Scope /Limitations
•
Surrogate’s consent is not required if the patient already made decisions about the proposed health care, expressed
orally or in writing or, with respect to a decision to withdraw or withhold life sustaining treatment expressed either orally
during hospitalization in the presence of two adult witnesses, at least one of whom is a health or social service
practitioner affiliated with the hospital, or in writing.
•
Mandated clinical criteria must be met in order for the surrogate to withhold or withdraw life sustaining treatment.
•
•

Surrogate List N.Y.S. Public Health Section 2994-d
List in Order of Priority
• A guardian authorized to decide about health care
pursuant to Article 81 of the Mental Hygiene Law
• Spouse or Domestic Partner
• Adult child
• Parent
• Adult Brother or Sister
• Close friend

Standards for Decisions By Surrogates
N.Y.S. Public Health Law Section 2994-d
Beneficial Treatment

Surrogate must decide in accordance with the patients wishes, including the patients religious and moral beliefs, or
in accordance with the patient’s best interests with a patient centered approach.
Withholding and Withdrawing of Life Sustaining Treatment –Criteria
Treatment would be an extraordinary burden to the patient and an attending determines, with the independent
concurrence of another physician, that to a reasonable degree of medical certainty and in accordance with accepted
medical standards that:
•
•
•

Patient has an illness or injury which can be expected to cause death within six months whether or not
treatment is provided, or the patient is permanently unconscious or,
If the patient is permanently unconscious, the attending physician determines, with the concurrence of another
attending physician, that the treatment would be an extraordinary burden to the patient or,
The provision of treatment would involve such pain and suffering or other burden that it would reasonably be
deemed inhumane, or extraordinarily burdensome under the circumstances, and the patient has an irreversible
or incurable condition as determined by an attending physician with the concurrence of another attending
physician to a reasonable degree of medical certainty and in accordance with accepted medical standards.

Standards for Decisions Without Surrogate
N.Y.S. Public Health Law Section 2994-g

FHCDA establishes a procedure for making health care decisions for patients who lack decisional capacity with no
available surrogate.
Routine Medical Care and Treatment
An attending physician shall be authorized to decide about routine medical treatment .
Major Medical Care and Treatment:
General Hospital
With respect to a decision to provide major medical treatment, the attending physician shall make a recommendation
in consultation with hospital staff directly responsible for the patient’s care.
At least one other physician designated by the hospital must independently determine that he or she concurs that the
recommendation is appropriate.
Residential Health Care Facility and Hospice
In a residential health care facility, and for a hospice patient not in a general hospital, the medical director of the
facility or hospice must independently determine that that he or she concurs that the recommendation is appropriate,
the second physician must be designated by the residential health care facility or hospice.
Any health or social service practitioner employed or affiliated with the facility or hospice may provide a second
opinion for decisions about physical restraints.

Standards- Patients Without a Surrogate
Withholding and Withdrawal of Life Sustaining Treatment
Judicial Determination
Court may determine the case based on statutory standards.
Attending Physician with the Concurrence of a Second Physician
The attending physician with the independent concurrence of a second physician designated by
the hospital, must determine to a reasonable degree of medical certainty:
 Life sustaining treatment offers the patient no medical benefit because the patient will die
imminently even if the treatment is provided; and
 The provision of life sustaining treatment would violate accepted medical standards.
Judicial Intervention
Court approval is not required.
However, this provision does not apply to any treatment necessary to alleviate pain or
discomfort.

Formal Recognition of Bioethics
N.Y.S. Public Health Law Section 2994-m
The FHCDA requires each hospital to establish an Ethics Review Committee.
Functions of the Committee:
•
Consider and respond to any health care matter presented to it by a person connected with a case.
•
May include advice and making recommendations about proposed health care.
•
Provide assistance in resolving disputes about proposed health care on ethical aspects of proposed health care.
Membership
•
Committee must be interdisciplinary and include at least five members who have demonstrated an interest in, or
commitment to, patient's rights or to the medical, public health, or social needs of those who are ill.
•
At least three ethics review committee members must be health or social services practitioners, at least one of whom must
be a registered nurse and one of whom must be a physician.
•
At least one member must be a person without any governance, employment or contractual relationship with the hospital.
Residential Healthcare Facility
•
In a residential health care facility the facility must offer the residents' council of the facility (or of another facility that
participates in the committee) the opportunity to appoint up to two persons to the ethics review committee, none of whom
may be a resident of or a family member of a resident of such facility, and both of whom shall be persons who have
expertise in or a demonstrated commitment to patient rights or to the care and treatment of the elderly or nursing home
residents through professional or community activities, other than activities performed as a health care provider.
Person Connected with the Case
A person connected with the case may not participate as an ethics review committee member in the consideration of that case.

Ethics Review Committee
Interventions
General Hospital with a Surrogate
In a general hospital, if the attending physician objects to a surrogate’s decision to withdraw or withhold nutrition and hydration
provided by means of medical treatment, in that the provision of treatment would involve such pain, suffering or other burden that it
would be reasonably inhumane or extraordinarily burdensome under the circumstances, and the patient has an irreversible condition or
incurable condition as determined by an attending physician with the concurrence of another physician to a reasonable degree of
medical certainty.
The decision shall not be implemented until an Ethics Review Committee including one physician not directly responsible for the care
or a Court reviews the decision and determination.
Emancipated Minor Patients
If the attending physician determines that a patient is an emancipated minor with decisional capacity, the patient shall have the
authority to decide about life sustaining treatment.
Such authority shall include a decision to withhold or withdraw life sustaining treatment if an attending physician and the ethics review
committee determine that the decision accords with the decision for surrogate decision making for adults and the ethics review
committee approves the decision.
Residential Health Care Facility with a Surrogate -Review of a Life Sustaining Treatment Determination
Surrogate shall have authority to refuse life sustaining treatment if the patient has an irreversible or incurable condition as determined
by the attending physician, with the concurrence of another attending physician, that the provision of treatment would involve such
pain and suffering or other burden that it would be reasonably deemed inhumane or extraordinarily burdensome under the
circumstances.
However, an Ethics review is required including one physician who is not directly responsible for the care, or a Court reviews the
decision.
Does not apply to decisions to withhold cardio pulmonary resuscitation.
.

Ethics Review Committee
Interventions
Concurring Physician Objection for Health Care Decisions for Adult Patients Without Surrogates
If a physician consulted for a concurring opinion objects to an attending physician's recommendation or determination or a member of
the hospital staff directly responsible for the patient’s care objects to an attending physicians recommendation about major medical
treatment or treatment without medical benefit, the matter shall be referred to the ethics review committee if it can not otherwise be
resolved.
Request by a Person Connected to the Case
A person connected with the case requests the ethics review committee to provide assistance in resolving a dispute about proposed
care:

•
•
•
•
•
•
•
•

Patient
Any person on the surrogate list
Parent or guardian of a minor patient
Hospital administrator
Attending physician
Any other health or social service provider who is or has been directly involved in patient care.
Any duly authorized state agency including the facility director or regional director for a patient transferred from a
mental hygiene facility.
The facility director for a patient transferred from a correctional facility.

Procedural Highlights
Ethics Review Committee
Response
The ethics review committee shall respond promptly, as required by the circumstances. The committee shall permit persons
connected with the case to present their views to the committee, and to have the option of being accompanied by an advisor when
participating in a committee meeting.
Notice
The ethics review committee shall provide the patient, when there is an indication of the patients ability to comprehend the information,
the surrogate and other persons directly involved in the decision or dispute regarding the patient’s care, or any parent or guardian of a
minor directly involved in the decision or dispute, an attending physician, and other persons the committee deems appropriate with the
following :
•
•

Notice of any pending case consideration concerning the patient, information about the ethics committees procedures,
composition and function and the committees response to the case following an ethics review concerning the withdrawal or
withholding of life sustaining treatment.
Treatment shall not be withdrawn or withheld until persons identified above have been informed of the committee’s decision.

Hospice
When an ethics review committee is convened to review decisions regarding hospice care for a patient in a general hospital or
residential health care facility, the responsibilities shall be carried out by the ethics review committee of the hospital or residential
facility provided that such a committee shall invite a representative from hospice to participate.

Bioethics in Medical Research
Karen L. Illuzzi Gallinari, Esq.
Healthcare Law, Compliance and Bioethics Specialist

Milestones in Research Ethics
• 1979 Belmont Report*, heavily influenced the “Common Rule”
• 1991 Federal Policy for the Protection of Human Subjects
(the “Common Rule”) was published.
(Adopted by 15 Federal departments and agencies)
• 2000 Further publicized ethical abuses prompting establishment
of the Office of Human Research Protections
• Full title is the Belmont Report: Ethical Principles and Guidelines for the Protection of Human
Subjects of Research, Report of the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research. Issued 30 September 1978, published FR 18 April
1979. Named for Belmont Conference Center, where the document was drafted in part.

Belmont Report
• 3 basic principles for ethical research
1. Respect for persons / individual autonomy
Risks involved and informed consent
2. Beneficence, benefit to the participant
3. Justice, risks and benefits equitably distributed

Final Amendment of
The Common Rule
• Federal Policy for the Protection of Human Subjects
• Originally published in 1991 and codified in by other Fed. depts/agencies
• Final amendment published January 19, 2017
• Implementation delayed at least until July 19, 2018, possibly Jan. 2019
• Comments regarding additional 6 month delay due by May 21, 2018.

Research Ethics and Biobanking
• A biobank is a collection of:
– health information linked to
– human specimens
o blood
o urine
o tissue samples
– available for Institutional Review Board (IRB) approved research

Future Advances in Medicine
• Personalized medicine is:
– Health care tailored to the
biological traits of individuals
• Has potential to improve:
– Prevention of disease
– Effectiveness of treatments
– Reactions to medication
• Requires:
– Large numbers of specimens
– Diverse races and ethnicities
– Linkage to computerized patient information

Legal and Ethical Requirements
FEDERAL
• Federal Common Rule to Ensure Protection of Human
Subjects (“The Common Rule”)
• Health Insurance Portability and Accountability Act
(“HIPAA/HITECH”) Final Omnibus Rule Jan. 2013
• Federal Genome-wide Association Studies Guidelines
• Food and Drug Administration Requirements

Legal and Ethical Requirements
NYS
– NY Pub. Hlth Law 24-A, Protection of Human Subjects*
– NY Civil Rights Law § 79-L.
Confidentiality of records of genetic tests
Addresses clinical and research testing
– 10 NYCRR Part 58-1, Section 1.8: Results of tests to be
reported only to physicians or other authorized persons
*NYSBA, Hlth Law Section, Medical Research/Biotech Committee proposal to

NYSDOH to permit research institutions which comply with the Common Rule to be in
compliance with NYS research requirements.

Risks of Biobank Participation
• Minimal
• Small privacy risk
• Rare chance of anxiety, if meaningful individual results become
available
– If so, private life, long-term care or disability insurance may
be affected
– Genetic counseling would be offered to help address risks of
learning individual genetic results

“Benefits” of Participation
• No direct benefit to individual patient
• Participation may help people in the future
• No payment of any kind for:
– Tests
– Treatments
– Products
– Other things of value which may result from the research

Other Important Issues
• Rare possibility of actionable patient specific results *
• Pediatric samples
• Adults who lack capacity
*NYSBA, Hlth Law Section, Medical Research/Biotech Committee proposal to

NYSDOH to amend 10 NYCRR Part 58-1, Section 1.8 To Permit research investigators to
report research findings which represent significant health risks to subject’s physician.

Key provisions of the Final Common Rule
• Does not expand the definition of “human subjects research” to
include research using anonymous or de-identified specimens
• Allows the use of “broad consent” for storage of and research on
identifiable biospecimens
• States intent to simplify informed consent documents, but includes
element on commercial gain
• Expands research that is “exempt” from regulation because of
low-risk, but requires limited review by an IRB
*See E.g., John Conley, Some Thoughts on the New Common Rule for Human Subjects Research, Genomics Law
Report, March 29, 2017.

National Biobank Initiatives
• Nat’l Instit. Of Hlth, “All of Us” https://allofus.nih.gov/
 One million participants
 2017 budget $230 million, $40 million from the 21st Century Cures
Act. Congress authorized $1.455 billion over 10 years
 The Struggle to Build a Massive ‘Biobank’ of Patient Data, NY Times,
Gina Kolata, March 19, 2018
 17,000 volunteers, “beta testers”, supplied blood and urine samples,
measurements taken, and surveys
 Geisinger and Kaiser Permanente, backed away from grants to
participate due to programs complexity
• Private ventures, EG. Regeneron, 300 Participants
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Why Mediation
• new player introduces “neutral turf”
• identifies styles/patterns of communication
• no “stake” in previous treatment decisions–
impartial to this situation
• less politically vulnerable (residents and
fellows)
• committed to empowering patients and family

STADA
•
•
•
•
•

Sit
Tell me about Mama
Admire
Discuss
Ask

Mediation
• It is a private, voluntary, informal process in which
an impartial third person facilitates a negotiation
between people in conflict and assists them to find
solutions that meet their interests and needs.
• The mediator works with the parties, helping them
identify their goals and priorities, generate and
explore options, and exchange information that
may be necessary in formulating a solution.
• Mediators are optimists who work to “LEVEL THE
PLAYING FIELD”.

Medical Facts
“Medical facts” can be defined as consensus
agreements among the staff regarding the
meaning of the medical narrative, the present
data, and the observations of staff regarding
the patient’s improvement or deterioration.
For the purposes of mediation, a medical fact
is an interpretation of data in a moment of
time by the most powerful player in the
discussion.

Mediation in Health Care Settings
Bioethics mediation combines the clinical
substance and perspective of bioethics
consultation with the tools of the mediation
process, using the techniques of mediation
and dispute resolution in order to:
• identify the parties to the conflict and seek
consensus

• Deciding Not to Reach a Resolution Is
Not an Option
• The Playing Field Is Usually Uneven for
Patients and Their Families
• Confidentiality Is Limited to
Information Not Relevant to Patient
Care
• Time Is of the Essence

Additional Roles of the
Consultant/Mediator

• teacher
• reference point for new literature
• mentor in the politics of medicine

Conclusion

Directions in Bioethics and Public Health:
Converging Perspectives
Mary Beth Morrissey, Esq., PhD, MPH
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Fordham University

Background and Work: Interdisciplinary
Interdisciplinary focus:
• Health law & policy
• Public health
• Bioethics
• Gerontological social work and pscyhological
research
• Medical and psychological humanities

Part I. Goals and contexts
• Paradigm shifts
• Key influences
• Convergences and directions

Paradigm Shifts
• Individual needs and interests understood in
relation to the other and in social and ecological
contexts
• Critique of neoliberalism as sociopolitical movement
and implications for bioethics (Morrissey, Lang &
Newman, in press, 2018; Sugarman, 2015)

Influence of Public Health
 Reframing obligation: obligation to individual and
community

Influence of Human Science Research and
Phenomenology
• Heightened focus on lived experience from
first-person perspective of experiencing
individual and individual’s life-world
• Transcendence of consciousness:
consciousness always directed to objects
outside itself - intentionality
• Role of reflection in understanding human
experience and intentionalities

Law and Bioethics
• Law as lived social practice
• Humanistic foundations of law (Vining, 2008)
• Understanding therapeutic benefits of law from
perspective of beneficiaries (Morrissey & Jennings,
2006)

Convergences of Bioethics and Public Health:
Directions
• Fostering a palliative ethic of care (Fins, 2006)
through relief of pain and suffering
• Moving away from technical rationality and rigid
principlism (Morrissey & Barber, 2014)
• Gaining deeper access to first-person experience
and life-historical narratives as person-inenvironment, embedded in social context and
community
• Democratizing knowledge through participatory
processes of deliberation and debate
• Making allocation of resource decisions explicit

Part II. The Role of Politics and Values in Research:
The Case of Medical Aid-in-Dying and Implications for
Bioethics and Public Health

Objectives: Ethics and Equity
• Frame --- and reframe --- the problem and narrative of terminal
illness and suffering, and give voice to those who are marginalized
and invisible – multiple stories
• Describe practice of Medical Aid in Dying and its implications for
interdisciplinary sciences – moving beyond medical to ethical
• Interpret available existing data
• Discuss relationship between values and research – focus on
Equity : Is Medical Aid in Dying a colonizing activity of nonHispanic white people? Are the social structures coercive?
• Call for more robust participatory action research designs

Framing of Social Problem
• High suffering burden in serious and terminal illness across
diverse populations and groups in United States and in New York
• Social and structural determinants of health, mental health and
well-being, such as income, education, housing, neighborhood and
food security
• Forms of structural discrimination that perpetuate inequities in
access to basic health care, hospice and palliative care, and
essential medicines
• Voices and stories that have not been heard
• Public Policy Goal: Attaining health care justice for all persons
by eliminating inequities

Key Issue: Equity
• Equity is fundamentally about fairness and just
distribution of resources.
• A central issue in Medical Aid in Dying is that of
equitable access to care and the social determinants of
health that influence equitable access to care.
• Call for more robust research about lived experiences
of persons with serious and terminal illness across
racially, ethnically and socioeconomically diverse
groups, and what they want at end of life.

What is Medical Aid in Dying?
• Medical Aid in Dying is a medical practice that would allow a
physician to prescribe a lethal medication to a mentally
competent, terminally ill individual who requests and
consents to such lethal medication for the purpose of ending
her/his own life.
• The term “physician aid in dying” has also been used to
describe physician-aided dying practice, which proponents
seek to differentiate from “physician assisted suicide.”
• The language of “hastening death” or “wish to hasten death”
has also been used in thse contexts (Balaguer et al., 2016).

NY Court of Appeals Decision and NY Bill
•

Myers v. Schneiderman NY Court of Appeals Decision (2017 N.Y. slip Op. 06412, 30 N.Y.3d
(2017) – suit sought recognition of a right to make autonomous decision to end one’s life
(choosing aid in dying) under NYS Constitution. HELD no constitutional right to aid in dying
in New York.

•

Bill introduced in NYS Legislature: A.2383/S.3151-A, 241st N.Y Leg. Sess. (2018), amending
A.2383 / S.3151 (2017).

•

Public Policy Issues:

– Beneficiaries: The bill appears to apply to all possible beneficiaries and therefore as presently written
would have universal application. For example, there are no residency requirements. (The six states and
the District of Columbia that have legalized aid in dying all have residency requirements.) There are also
no safeguards for institutionalized persons such as nursing home residents or inmates.
– Financing and Delivery Systems: No information.

Alternative to Palliative Care: Allocation of
Resources?
• Alternative Option: The proposed bill would position Medical Aid in Dying as an
alternative to palliative care. Practically, it is unclear what this would mean and how
it would be operationalized.
• Would New York now require that Medical Aid in Dying be included in palliative and
end-of-life options offered to patients under the NY Palliative Care Information Act
and Palliative Care Access Act?
• What are the public policy choices and decisions that need to be debated and
made about allocation of resources to palliative care and Medical Aid in Dying if
they are structured as care alternatives?

Palliative Care Patient Information Act, N.Y. Public Health Law § 2997-c(2) (PHL);
Palliative Care Access Act, PHL § 2997-d

Dearth of Research
• Dearth of Research: Few investigations of the personal, social and cultural
meanings associated with desires to end one’s own life, espercially among
racially and ethnically diverse groups.
• Public Health Data: Oregon and Washington (based on information
collected from After Death Forms and Physician Compliance Forms); data
from other states not available (California, Montana, Vermont, Colorado and
DC)
• Types of studies: retrospective using public health data; cross-sectional;
studies of Oregonians interested in DWD
• Limitations: public health data collected from physician and other records;
aid in dying advocacy organizations may introduce bias into recruitment of
study participants; constraints on interviews with very sick people

Oregon Data: Twenty Year Picture
• Over 20 years, 1,975 persons obtained
prescriptions and 1,275 died from ingestion (under
two thirds)
• 99.7% of population did not take advantage of the
law
• Oregon’s population is not as racially and ethnically
diverse or economically segregated as New York.
Oregon Public Health Division, Oregon Death with Dignity Act: 2017 Data Summary. Oregon Health Authority (February 9, 2018),

Snapshot of Oregon Data

Oregon DWD Historical Data

Washington: Death with Dignity Data 2015
and 2014 (Sex, Age, Race and Ethnicity, Marital Status)

Washington DWD Historical Data

Comparison Data Oregon & Washington 2015

Comparison Data Oregon & Washington 2015

Schoepfer Study: Role of Social Support
• Mixed method study of competent, terminally ill older
adults (50 and over)
• Purposive sampling across care settings (N=96)
• 84% White
• Findings: relationship between consideration to hasten
death and “social support”
• “Poor or conflictual social support was experienced by
33.3% of the respondents who considered a hastened
death but only 2.6% of those not considering one.”
(Schroepfer, 2008, p. 616)

Call for Debate and deliberation and Welldesigned research
• City Bar Commentary (June 2017)
• Hearings in NY – May 3, 2018, NYC
• More public debate and deliberation
• Well-designed research studies

